Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Mechanisms of Disease: mechanisms of hepatic fibrosis and therapeutic implications

Abstract

Hepatic fibrosis, or scarring of the liver, is emerging as a treatable complication of advanced liver disease, following significant progress in understanding its underlying mechanisms. Efforts have focused on the hepatic stellate cell, as these cells can undergo 'activation' into proliferative and fibrogenic myofibroblast-like cells during liver injury. Stimuli driving stellate cell activation include hepatocellular necrosis due to oxidant stress, apoptosis, and soluble growth factors. Specific lymphocyte subsets can also stimulate fibrogenesis. A cascade of signaling and transcriptional events in stellate cells underlies the fibrogenic response to liver injury, with each step in the cascade being a potential target for antifibrotic therapy. Disease-specific fibrogenic mechanisms have also been uncovered: in hepatitis C, this may include direct stimulation of stellate cell activation by viral infection; in nonalcoholic steatohepatitis, elevated levels of leptin and increased leptin signaling by stellate cells increase fibrogenesis. Determinants of fibrosis progression include both environmental and genetic factors, with ongoing efforts to define specific polymorphisms correlating with fibrosis progression rates. Human studies now indicate that fibrosis and even cirrhosis could be reversible, especially if the underlying disease is eradicated. A key challenge is to establish noninvasive means of assessing fibrosis stage and progression using either serum tests and/or imaging. In addition, endpoints of antifibrotic clinical trials need to be established so that reliable evidence of benefit can be identified. We are on the cusp of a new era in which antifibrotic therapies could become important in treating chronic fibrosing liver disease.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The effects of liver fibrosis on hepatic sinusoidal cells.
Figure 2: Hepatic stellate cell activation.

Similar content being viewed by others

References

  1. Friedman SL (2000) Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 275: 2247–2250

    Article  CAS  Google Scholar 

  2. Schuppan D et al. (2001) Matrix as modulator of stellate cell and hepatic fibrogenesis. Semin Liver Dis 21: 351–372

    Article  CAS  Google Scholar 

  3. Geerts A (2001) History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis 21: 311–335

    Article  CAS  Google Scholar 

  4. Pinzani M and Marra F (2001) Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 21: 397–416

    Article  CAS  Google Scholar 

  5. Rockey D (2003) Vascular mediators in the injured liver. Hepatology 37: 4–12

    Article  CAS  Google Scholar 

  6. Kinnman N et al. (2003) The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis. Lab Invest 83: 163–173

    Article  CAS  Google Scholar 

  7. Cassiman D et al. (2002) Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J Hepatol 36: 200–209

    Article  Google Scholar 

  8. Corpechot C et al. (2002) Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 35: 1010–1021

    Article  CAS  Google Scholar 

  9. Forbes SJ et al. (2004) A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology 126: 955–963

    Article  Google Scholar 

  10. Magness ST et al. (2004) A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations. Hepatology 40: 1151–1159

    Article  CAS  Google Scholar 

  11. Kalluri R and Neilson EG (2003) Epithelial–mesenchymal transition and its implications for fibrosis. J Clin Invest 112: 1776–1784

    Article  CAS  Google Scholar 

  12. Tsukamoto H (2002) Redox regulation of cytokine expression in Kupffer cells. Antioxid Redox Signal 4: 741–748

    Article  CAS  Google Scholar 

  13. Bataller R et al. (2003) NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 112: 1383–1394

    Article  CAS  Google Scholar 

  14. Tuma DJ (2002) Role of malondialdehyde–acetaldehyde adducts in liver injury. Free Radic Biol Med 32: 303–308

    Article  CAS  Google Scholar 

  15. Canbay A et al. (2003) Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 83: 655–663

    Article  CAS  Google Scholar 

  16. Canbay A et al. (2002) Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 123: 1323–1330

    Article  CAS  Google Scholar 

  17. LeCouter J et al. (2003) Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 299: 890–893

    Article  CAS  Google Scholar 

  18. Olaso E et al. (2003) Proangiogenic role of tumor-activated hepatic stellate cells in experimental melanoma metastasis. Hepatology 37: 674–685

    Article  CAS  Google Scholar 

  19. Marra F (2002) Chemokines in liver inflammation and fibrosis. Front Biosci 7: d1899–d1914

    Article  CAS  Google Scholar 

  20. Yoshiji H et al. (2003) Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 52: 1347–1354

    Article  CAS  Google Scholar 

  21. Ankoma-Sey et al. (2000) Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells. Hepatology 31: 141–148

    Article  CAS  Google Scholar 

  22. Schwabe RF et al. (2003) Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. Am J Physiol Gastrointest Liver Physiol 285: G949–G958

    Article  CAS  Google Scholar 

  23. Bataller R et al. (2004) Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 126: 529–540

    Article  CAS  Google Scholar 

  24. Efsen E et al. (2002) Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans. J Hepatol 37: 39–47

    Article  CAS  Google Scholar 

  25. Paik YH et al. (2003) Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 37: 1043–1055

    Article  CAS  Google Scholar 

  26. Kobayashi S et al. (2003) Apoptosis of T cells in the hepatic fibrotic tissue of the rat: a possible inducing role of hepatic myofibroblast-like cells. Cell Tissue Res 311: 353–364

    PubMed  Google Scholar 

  27. Shi Z et al. (1997) Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc Natl Acad Sci USA 94: 10663–10668

    Article  CAS  Google Scholar 

  28. Hillebrandt S et al. (2002) Genome-wide analysis of hepatic fibrosis in inbred mice identifies the susceptibility locus Hfib1 on chromosome 15. Gastroenterology 123: 2041–2051

    Article  CAS  Google Scholar 

  29. Safadi R et al. (2004) Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology 127: 870–882

    Article  CAS  Google Scholar 

  30. Rachfal AW and Brigstock DR (2003) Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis. Hepatol Res 26: 1–9

    Article  CAS  Google Scholar 

  31. Mann DA and Smart DE (2002) Transcriptional regulation of hepatic stellate cell activation. Gut 50: 891–896

    Article  CAS  Google Scholar 

  32. Hellemans K et al. (2003) Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology 124: 184–201

    Article  CAS  Google Scholar 

  33. Marra F et al. (2000) Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 119: 466–478

    Article  CAS  Google Scholar 

  34. Miyahara T et al. (2000) Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 275: 35715–35722

    Article  CAS  Google Scholar 

  35. Hellemans K et al. (2004) Differential modulation of rat hepatic stellate phenotype by natural and synthetic retinoids. Hepatology 39: 97–108

    Article  CAS  Google Scholar 

  36. Kalinichenko VV et al. (2003) Foxf1 +/− mice exhibit defective stellate cell activation and abnormal liver regeneration following CCl4 injury. Hepatology 37: 107–117

    Article  CAS  Google Scholar 

  37. Yang C et al. (2003) Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors. Gastroenterology 124: 147–159

    Article  CAS  Google Scholar 

  38. Bonacchi A et al. (2003) The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C. Gastroenterology 125: 1060–1076

    Article  CAS  Google Scholar 

  39. Pohlmann S et al. (2003) Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol 77: 4070–4080

    Article  CAS  Google Scholar 

  40. Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346: 1221–1031

    Article  CAS  Google Scholar 

  41. Ikejima K et al. (2002) Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 122: 1399–1410

    Article  CAS  Google Scholar 

  42. Leclercq IA et al. (2002) Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 37: 206–213

    Article  CAS  Google Scholar 

  43. Saxena NK et al. (2003) Leptin induces increased alpha2(I) collagen gene expression in cultured rat hepatic stellate cells. J Cell Biochem 89: 311–320

    Article  CAS  Google Scholar 

  44. Kamada Y et al. (2003) Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 125: 1796–1807

    Article  CAS  Google Scholar 

  45. Bonis PA et al. (2001) Is liver fibrosis reversible? N Engl J Med 344: 452–454

    Article  CAS  Google Scholar 

  46. Desmet VJ and Roskams T (2004) Cirrhosis reversal: a duel between dogma and myth. J Hepatol 40: 860–867

    Article  Google Scholar 

  47. Poynard T et al. (2002) Impact of pegylated interferon alpha-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122: 1303–1313

    Article  CAS  Google Scholar 

  48. Murphy FR et al. (2002) Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem 277: 11069–11076

    Article  CAS  Google Scholar 

  49. Wanless IR et al. (2000) Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 124: 1599–1607

    CAS  PubMed  Google Scholar 

  50. Issa R et al. (2004) Spontaneous recovery from micronodular cirrhosis: Evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 126: 1795–1808

    Article  CAS  Google Scholar 

  51. Bataller R et al. (2003) Genetic polymorphisms and the progression of liver fibrosis: A critical appraisal. Hepatology 37: 493–503

    Article  CAS  Google Scholar 

  52. Albanis E and Friedman SL (2002) Non-invasive markers of hepatic fibrosis. Clin Perspect Gastroenterol 5: 182–187

    Google Scholar 

  53. Callewaert N et al. (2004) Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 10: 429–434

    Article  CAS  Google Scholar 

  54. Pinzani M and Rombouts K (2004) Liver fibrosis: from the bench to clinical targets. Dig Liver Dis 36: 231–242

    Article  CAS  Google Scholar 

  55. Schuppan D and Porov Y (2002) Hepatic fibrosis: From bench to bedside. J Gastroenterol Hepatol 17 (Suppl 3): S300–S305

    Article  Google Scholar 

  56. Friedman SL and Arthur MJP (2002) Reversing hepatic fibrosis. Sci Med 8: 194–205

    CAS  Google Scholar 

Download references

Acknowledgements

The author's studies are supported by grants from the NIDDK, the Feld Foundation and the US Department of Defense. I wish to acknowledge the many outstanding publications from colleagues in the field whose work could not be cited because of space constraints.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Scott L Friedman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Friedman, S. Mechanisms of Disease: mechanisms of hepatic fibrosis and therapeutic implications. Nat Rev Gastroenterol Hepatol 1, 98–105 (2004). https://doi.org/10.1038/ncpgasthep0055

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0055

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing